CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities:
Net income	$ 86,139	$ 41,949
Adjustments to reconcile net income to net cash provided by operating activities:
Change in estimated fair value of contingent liabilities	(33)	(670)
Depreciation and amortization of intangible assets	8,765	9,499
Amortization of premium on investments, net	(157)	(282)
Amortization of debt discount and issuance fees	84	95
Non-cash income from financial royalty assets	0	(379)
CECL adjustment to financial royalty assets	(2,841)	0
Gain on derivative instruments	(196)	0
Losses from equity method investment in Primrose Bio	2,352	0
Share-based compensation	7,334	5,931
Deferred income taxes	19,546	8,754
Gain from short-term investments	(110,772)	(39,533)
Lease amortization expense	478	447
Other	(210)	240
Changes in operating assets and liabilities, net of acquisition:
Accounts receivable	3,462	1,099
Inventory	2,632	2,035
Accounts payable and accrued liabilities	(1,382)	(435)
Income tax receivable and payable	7,533	4,614
Deferred revenue	(540)	(98)
Other assets and liabilities	(3,462)	682
Net cash provided by operating activities	18,732	33,948
Cash flows from investing activities:
Purchase of financial royalty assets	(2,443)	0
Proceeds from financial royalty assets	1,942	130
Purchase of short-term investments	(77,634)	(39,864)
Proceeds from sale of short-term investments	60,919	44,232
Proceeds from maturity of short-term investments	14,544	8,465
Purchase of property and equipment	(105)	(2,414)
Net cash (used in) provided by investing activities	(3,775)	10,549
Cash flows from financing activities:
Payments under finance lease obligations	(5)	(13)
Net proceeds from stock option exercises and ESPP	15,304	3,393
Taxes paid related to net share settlement of equity awards	(3,076)	(4,155)
Cash paid for debt issuance costs	(41)	0
Net cash provided by (used in) financing activities	12,182	(775)
Net increase in cash and cash equivalents	27,139	43,722
Cash and cash equivalents at beginning of period	22,954	45,006
Cash and cash equivalents at end of period	50,093	88,728
Supplemental disclosure of cash flow information:
Interest paid	59	0
Supplemental schedule of non-cash activity:
Accrued financial royalty asset purchases	2,129	0
Accrued fixed asset purchases	2	140
Unrealized gain (loss) on AFS investments, net of tax	(93)	49
Primrose Bio
Cash flows from investing activities:
Cash paid for investment in Primrose Bio	$ (998)	$ 0